Quest Diagnostics Offers Agilent’s Resolution ctDx FIRST Liquid Biopsy Test
The liquid biopsy ctDx FIRST test is FDA approved as a companion diagnostic for advanced non-small cell lung cancer (NSCLC) patients.
Read MorePosted by Andy Lundin | Jan 23, 2023 | Immunoassay Reagents & test Kits, Lung Cancer, Sequencing Systems |
The liquid biopsy ctDx FIRST test is FDA approved as a companion diagnostic for advanced non-small cell lung cancer (NSCLC) patients.
Read MorePosted by Andy Lundin | Jan 20, 2023 | Diagnostic Technologies |
Biomedical engineers say interstitial fluid could provide an excellent medium for early disease diagnosis or long-term health monitoring.
Read MorePosted by Andy Lundin | Jan 19, 2023 | Disease States |
Selux received 510(k) clearance for its a rapid antibiotic susceptibility testing platform that offers targeted therapeutic results quickly.
Read MorePosted by Andy Lundin | Jan 18, 2023 | Diagnostic Technologies |
ALiA BioTech is ready to deploy a rapid diagnostic platform that can conduct multiplex testing in a single biochip within 15 minutes.
Read MorePosted by Andy Lundin | Jan 18, 2023 | Colorectal |
Helio Genomics unveiled positive finds of its multimodal epigenetic sequencing assay (MESA) for colon cancer detection.
Read More